Greenwich Pharmaceuticals Inc. announced Tuesday that it hasfiled product license applications (PLAs) for Therafectin inFrance and the Netherlands.
The Fort Washington, Pa., company (NASDAQ:GRPI) has alreadyfiled PLAs -- the equivalents of new drug applications (NDAs)in the U.S. -- in the United Kingdom and Ireland forTherafectin, which is a synthetic carbohydrate for treatingrheumatoid arthritis. Greenwich filed its NDA in the U.S. onTherafectin in March.
(c) 1997 American Health Consultants. All rights reserved.